First trimester fetal nuchal translucency.
This review examines the development of a new method of screening for Down's syndrome based on the combination of fetal nuchal translucency thickness, maternal age and maternal serum biochemistry at 10-14 weeks of gestation. This method can potentially identify more than 80% of affected fetuses for a false-positive rate of less than 5%.
Pandya
P P
PP
Harris Birthright Research Center for Fetal Medicine, King's College Hospital Medical School, London, UK.
Santiago
C
C
Snijders
R J
RJ
Nicolaides
K H
KH
D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D002869:Chromosome Aberrations / Q000175:diagnosis / Q000000981:diagnostic imaging*; D025063:Chromosome Disorders; D004314:Down Syndrome / Q000175:diagnosis / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D008423:Maternal Age; D009333:Neck / Q000000981:diagnostic imaging; D010446:Peptide Fragments / Q000097:blood; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D011296:Prenatal Diagnosis; D012680:Sensitivity and Specificity; D016216:Ultrasonography, Prenatal
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D011266:Pregnancy-Associated Plasma Protein-A